Evidence map›Paper›PMID 21390568›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2012

Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.

Jin Won Kim, Yongjun Cha, Su-Jung Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo and 1 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Efficacy of different pharmaceutical forms ofFrontiers in pharmacology · 2025
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Dermatologic conditions in women receiving systemic cancer therapy.International journal of women's dermatology · 2019
    Review
  13. Burden of oral mucositis in stem cell transplant patients-the patients' perspective.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
  14. The effect of preventive oral care on treatment outcomes of a cohort of oral cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Article
  15. Review
  16. Supportive cryotherapy: a review from head to toe.Journal of pain and symptom management · 2014
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jin Won KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, South Korea.
Yongjun Cha
Su-Jung Kim
Sae-Won Han
Do-Youn Oh
Se-Hoon Lee
Dong-Wan Kim
Seock-Ah Im
Tae-You Kim
Dae Seog Heo
Yung-Jue Bang
Seoul National University Hospital · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study aims to determine whether or not oral mucositis (OM) during active chemotherapy in patients with solid tumors is representative of the patient's quality of life (QOL) and the suffering from adverse effects.

methodsFrom October 2007 to September 2008, we prospectively enrolled 344 consecutive patients with solid tumors who initiated a new chemotherapy regimen. OM, other adverse effects, and the QOL were surveyed by face-to-face interviews and patient diaries.

resultsOM developed during 175 of 633 cycles (27.7%). Forty-five percent of the patients experienced OM during two cycles of chemotherapy. The QOL in patients with OM was significantly lower than patients without OM, as evaluated by the Functional Assessment of Cancer Therapy-General (70.26 ± 15.36 and 75.09 ± 13.12, respectively; p < 0.001). Specifically, the physical and emotional well-being was lower in patients with OM compared with patients without OM. Moreover, other adverse effects were more frequent in chemotherapy cycles with OM compared with chemotherapy cycles without OM (amount of food intake, activity, nausea, vomiting, fever, myalgias, and sensory neuropathy; p < 0.001, p = 0.008, p < 0.001, p = 0.001, p = 0.002, p < 0.001, and p < 0.001, respectively).

conclusionsOM represents poor QOL and is a basic symptom of symptom clusters in patients with solid tumors receiving active chemotherapy.

Indexed as

Quality of LifeAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedNeoplasmsProspective StudiesStomatitisAntineoplastic Agents

Identifiers

PMID21390568
OpenAlexW2015416409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.